Supernus Pharmaceuticals (NASDAQ:SUPN) Downgraded by Zacks Research to “Hold”

Zacks Research cut shares of Supernus Pharmaceuticals (NASDAQ:SUPN) from a strong-buy rating to a hold rating in a report released on Tuesday morning,Zacks reports.

Several other research firms have also recently weighed in on SUPN. Wall Street Zen cut shares of Supernus Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Saturday, August 8th. Weiss Ratings cut Supernus Pharmaceuticals from a “sell (d+)” rating to a “sell (d-)” rating in a report on Friday, October 30th. Cantor Fitzgerald boosted their price objective on Supernus Pharmaceuticals from $67.00 to $87.00 and gave the stock an “overweight” rating in a report on Wednesday. Piper Sandler started coverage on Supernus Pharmaceuticals in a research report on Wednesday. They issued an “overweight” rating and a $47.00 target price on the stock. Finally, Jefferies Financial Group assumed coverage on Supernus Pharmaceuticals in a research note on Wednesday. They set a “strong-buy” rating on the stock. One investment analyst has rated the stock with a Strong Buy rating, two have given a Buy rating, two have given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $63.50.

Supernus Pharmaceuticals Price Performance

Shares of SUPN opened at $28.21 on Tuesday. The company’s 50-day moving average is $41.74 and its 200-day moving average is $47.04. The firm has a market capitalization of $3.33 billion, a PE ratio of 7.88 and a beta of 0.84. Supernus Pharmaceuticals has a fifty-two week low of $26.74 and a fifty-two week high of $42.81.

Supernus Pharmaceuticals (NASDAQ:SUPN) last announced its earnings results on Thursday, October 29th. The specialty pharmaceutical company reported $0.35 EPS for the quarter, missing the consensus estimate of $0.49 by ($0.14). The company had revenue of $208.60 million for the quarter, compared to the consensus estimate of $217.56 million. Supernus Pharmaceuticals had a negative return on equity of 418.04% and a net margin of 32.75%. The business’s quarterly revenue was up 18.0% on a year-over-year basis. During the same period in the previous year, the firm posted ($0.80) EPS. Analysts predict that Supernus Pharmaceuticals will post 3.66 earnings per share for the current fiscal year.

Supernus Pharmaceuticals Announces Dividend

The firm also recently declared a special dividend, which will be paid on Friday, November 6th. Investors of record on Friday, October 30th will be paid a $8.13 dividend.

Hedge Funds Weigh In On Supernus Pharmaceuticals

A number of hedge funds have recently bought and sold shares of SUPN. Equitec Proprietary Markets LLC acquired a new stake in Supernus Pharmaceuticals in the 3rd quarter worth about $143,000. Pictet Asset Management Holding SA boosted its holdings in Supernus Pharmaceuticals by 0.6% in the 3rd quarter. Pictet Asset Management Holding SA now owns 434,915 shares of the specialty pharmaceutical company’s stock valued at $19,116,000 after purchasing an additional 2,437 shares during the period. CenterBook Partners LP acquired a new position in shares of Supernus Pharmaceuticals during the 3rd quarter worth approximately $876,000. Heritage Family Offices LLP acquired a new position in shares of Supernus Pharmaceuticals during the 3rd quarter worth approximately $39,000. Finally, Mirae Asset Global Investments Co. Ltd. bought a new position in shares of Supernus Pharmaceuticals during the third quarter worth approximately $128,000. 60.33% of the stock is owned by institutional investors.

Key Stories Impacting Supernus Pharmaceuticals

Here are the key news stories impacting Supernus Pharmaceuticals this week:

• Positive Sentiment: Cantor Fitzgerald raised its price target to $87 and maintained an “overweight” rating, signaling substantial potential upside in the firm’s view. However, the target may not reflect the completed merger or subsequent listing changes. Cantor Fitzgerald rating information
• Positive Sentiment: Recent commentary describes SUPN as potentially undervalued, citing ONAPGO’s exclusivity and the combined company’s prospects. These are valuation arguments, not company guidance. Supernus after its Indivior merger looks undervalued Supernus may be undervalued after ONAPGO exclusivity
• Positive Sentiment: One report highlights $473 million in shareholder payouts, a potentially favorable one-time return of capital. Supernus sends $473 million to shareholders
• Neutral Sentiment: Supernus completed its merger with Indivior, creating a CNS-focused biopharmaceutical company. The combination could broaden the business, but investors will assess the merged company’s prospects and integration. Supernus completes merger with Indivior
• Negative Sentiment: The merger and reported Nasdaq delisting raise uncertainty for investors holding SUPN: the shares may no longer trade as a standalone Nasdaq-listed security, limiting the relevance of older SUPN targets and comparisons. Changes after Supernus’s Nasdaq delisting and merger

About Supernus Pharmaceuticals

Supernus Pharmaceuticals, Inc is a specialty pharmaceutical company focused on developing and commercializing therapies for disorders of the central nervous system. The company’s activities center on epilepsy, attention-deficit/hyperactivity disorder (ADHD), and other neurological conditions, with an emphasis on products designed to provide differentiated dosing or delivery characteristics.

Supernus’ marketed products include Trokendi XR (topiramate extended-release) for the prevention of migraine headaches and the treatment of certain seizure disorders, Oxtellar XR (oxcarbazepine extended-release) for partial-onset seizures, and Qelbree (viloxazine extended-release) for ADHD in patients six years of age and older.